3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 2/3
1
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Conditions
Prostatic Neoplasms
3
Lymphoma
2
The Neoadjuvant Therapy
1
Sarcoma, Ewing
1
Sarcoma
1
Osteosarcoma
1
Neoplasms
1
Neoplasm Metastasis
1
Castration-resistant Prostate Cancer Patients with Oligometastases
1
Interventions
Trimethoprim, Sulfamethoxazole Drug Combination
4
gamma-Globulins
3
Standard of Care
3
Oxaliplatin
3
Melatonin
3
Gemcitabine
3
Fluorouracil
3
Drug Therapy
3
Ciprofloxacin
3
Capecitabine
3
pertuzumab
2
entrectinib
2
cobimetinib
2
capmatinib
2
atezolizumab
2
alectinib
2
Water
2
Vemurafenib
2
Trastuzumab
2
Sirolimus
2
Saline Solution
2
Pemetrexed
2
Methylphenidate
2
Lidocaine
2
Leucovorin
2
Immunoglobulins, Intravenous
2
Docetaxel
2
Dexmedetomidine
2
Cisplatin
2
Carboplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Neoplasms
×
Triptorelin Pamoate
×
Clear all
NCT02856048
2019-12-17
PRESOV
Assistance Publique - Hôpitaux de Paris
Phase 2/3
Unknown
11 enrolled